AnaptysBio stock rating maintained at Outperform by Wolfe Research

On Monday, Wolfe Research affirmed an Outperform rating for AnaptysBio Inc. (NASDAQ:ANAB) with a price target of $78.00. This represents a potential 39% increase from the stock's current price of $56.28. The rating was based on the firm's assessment of legal proceedings between AnaptysBio and GSK, specifically regarding Jemperli, a drug developed under a partnership.

The exact terms of the amendment agreement between the two parties are ambiguous, with potential support for both parties' interpretations. Wolfe Research believes that Tesaro may not be fulfilling its contractual obligations to maximize Jemperli's commercial potential. Tesaro has been reported to have become a non-operational entity, lacking employees or an independent development organization.

This has raised concerns about the company's ability to meet its contractual responsibilities. InvestingPro subscribers have access to additional insights on AnaptysBio's financial position and valuation metrics. Meanwhile, other analysts have also commented on AnaptysBio's stock. TD Cowen lowered its price target to $70, maintaining a Buy rating, while H.C.

Wainwright initiated coverage with a Buy rating and a higher target price of $95. These developments indicate ongoing interest and analysis surrounding AnaptysBio and its related ventures.